Mereo BioPharma’s BPS-804 drug accepted for participation in EMA’s adaptive pathways programme
Pharmaceutical Technology | February 21, 2017
UK-based biopharmaceutical company Mereo BioPharma has announced that its BPS-804 drug has been accepted to participate in the European Medicines Agency’s (EMA) adaptive pathways programme. As part of the adaptive pathways approach, EMA aims to improve timely access for patients to new medicines, primarily in areas of high medical need.